L-113-2022
Agreement ID
L-113-2022
Lead IC
NCI
Exclusivity
Nonexclusive
External Party
Lyell Immunopharma, Inc.
Fiscal Year
2022
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies